Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1744 + tiotropium dose-finding crossover study in COPD
2008-000562-23Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olodaterol and tiotropium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Trough FEV1 response after 4 weeks. Started Apr 2008; status: completed.
02
Drugs
olodateroltiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2008-000562-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000562-23.